Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel.

Key details:

• Marc H. Hedrick, M.D., President and CEO of Plus Therapeutics, will present a corporate overview
• The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET
• A replay will be accessible for 90 days on the company's website
• Management will be available for one-on-one meetings during the conference

Investors and interested parties can access the webcast and register for the conference through the provided links.

AUSTIN, Texas, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer will present a corporate overview at the H.C. Wainwright 26^th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.

Presentation Time: Monday, September 9, 2024, available on-demand starting at 7:00 AM ET

Webcast Link: Here

A replay of this presentation will be available for 90 days following the date of the presentation on the Company’s website at: https://ir.plustherapeutics.com/events

Management will be available for one-on-one meetings at the conference. To request a meeting and to register for the conference, click here: https://hcwevents.com/annualconference/

About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.

Cautionary Statement Regarding Forward-Looking Statements
This presentation contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of Rhenium (¹⁸⁶Re) Obisbemeda including the ability of Rhenium (¹⁸⁶Re) Obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC, clinical trials; possible negative effects of Rhenium (¹⁸⁶Re) Obisbemeda; the continued evaluation of Rhenium (¹⁸⁶Re) Obisbemeda including through evaluations in additional patient cohorts; the intended functions of the Company’s platform and expected benefits from such functions; and the development, utility and potential of the CNSide leptomeningeal metastases diagnostic test.

The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com

FAQ

When is Plus Therapeutics (PSTV) presenting at the H.C. Wainwright Global Investment Conference?

Plus Therapeutics (PSTV) is presenting on Monday, September 9, 2024, with the presentation available on-demand starting at 7:00 AM ET.

Who will be presenting for Plus Therapeutics (PSTV) at the H.C. Wainwright conference?

Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present a corporate overview at the conference.

Where can I watch the replay of Plus Therapeutics' (PSTV) presentation?

A replay of the presentation will be available for 90 days on the company's website at https://ir.plustherapeutics.com/events.

What is the focus of Plus Therapeutics' (PSTV) research and development?

Plus Therapeutics (PSTV) is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers.

How can investors request a meeting with Plus Therapeutics (PSTV) management at the conference?

Investors can request a meeting and register for the conference by visiting https://hcwevents.com/annualconference/.